Properties (60)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:analyzes |
gptkb:Dr._John_Smith
|
| gptkbp:built |
funding limitations
|
| gptkbp:campusFacilities |
gptkb:XYZ_Pharmaceuticals
|
| gptkbp:chemicalFormula |
contains thiazole ring
stable under room temperature C20H22N2O2 piperazine derivatives |
| gptkbp:clinicalTrials |
gptkb:United_States
positive efficacy Phase I completed reduction in anxiety symptoms |
| gptkbp:collaborations |
gptkb:University_of_ABC
|
| gptkbp:community_service |
generally positive
|
| gptkbp:compatibleWith |
high affinity for serotonin receptors
|
| gptkbp:competitors |
high
|
| gptkbp:complications |
headache
|
| gptkbp:composedOf |
multi-step synthesis
|
| gptkbp:dissolved |
soluble in DMSO
|
| gptkbp:dosageForm |
50-200 mg/day
|
| gptkbp:drugInterdiction |
moderate bioavailability
minimal interactions serotonin modulation |
| gptkbp:enrollment |
adults
patients with anxiety disorders |
| gptkbp:fauna |
rat model
|
| gptkbp:formulation |
tablet form
|
| gptkbp:funding |
NIH grant
|
| gptkbp:future_plans |
further clinical trials
|
| https://www.w3.org/2000/01/rdf-schema#label |
IMX029
|
| gptkbp:impact |
nausea
12 weeks favorable |
| gptkbp:is_studied_in |
randomized controlled trial
|
| gptkbp:is_used_in |
treatment of neurological disorders
|
| gptkbp:isATypeOf |
123456-78-9
|
| gptkbp:market |
not yet marketed
|
| gptkbp:number_of_stages |
Phase II
|
| gptkbp:operational_status |
clinical trials
|
| gptkbp:origin |
(2S)-2-(4-(4-(2-(4-(trifluoromethyl)phenyl)piperazin-1-yl)butyl)phenyl)thiazol-4-yl)acetamide
|
| gptkbp:patentStatus |
patented
|
| gptkbp:placeOfDeath |
placebo-controlled trial
|
| gptkbp:publications |
Journal of Medicinal Chemistry
approved by ethics committee |
| gptkbp:regulatoryCompliance |
under investigation
|
| gptkbp:related_to |
gptkb:IMX030
|
| gptkbp:releaseYear |
2005
|
| gptkbp:research_areas |
psychiatry
|
| gptkbp:research_focus |
anxiety disorders
preclinical studies |
| gptkbp:researchAndDevelopment |
promising results
|
| gptkbp:route |
oral
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:safetyFeatures |
ongoing
ongoing monitoring |
| gptkbp:sponsor |
gptkb:XYZ_Pharmaceuticals
|
| gptkbp:targets |
depression
serotonin receptor |
| gptkbp:triggerType |
serotonin reuptake inhibition
|
| gptkbp:weight |
338.4 g/mol
|